And if Jason's LymPro revenue estimates are proven to be unrealistic, as I believe they will be, the need for cash to support ongoing clinical trials will be less of a concern. Some are worrying about this now. I tend not to worry about things that haven't happened yet, and may not happen at all if the company's plan proves to be sound.